ROTH Capital Partners' Joseph Pantginis Interviewed by The Life Sciences Report
SAN FRANCISCO, CA--(Marketwired - April 28, 2016) - ROTH Capital Partners' Joseph Pantginis falls into that old-fashioned category of analysts who believe that good data can't help but drive a stock, no matter how far into the depths it may have sunk. In this interview with The Life Sciences Report, Pantginis presents his detailed growth theory on two names, and he leaves two Focus Picks on the table for investors to do further diligence on.
Included in this interview are: Rexahn Pharmaceuticals Inc. (NYSE MKT: RNN), Immune Pharmaceuticals Inc. (IMNP).
The Life Sciences Report : ROTH held its 28th Annual Growth Stock Conference in mid-March. Was it attended well? How did it go?
Joseph Pantginis: It was very successful. More than 500 companies presented, and it drew a lot of different types of investors to beautiful Dana Point in southern California. The conference is focused on emerging growth companies, but we had some larger-cap companies present as well. It was quite successful, especially given the market volatility.
TLSR: You follow leading-edge biotechnology companies, and talk to buyside people every day. What are buysiders thinking about now? What are their concerns?
JP: Over the last six months especially, a lot of focus has been on the extreme volatility, especially to the downside, in the biotech markets. There has been a flight from speculative, small- to mid-cap biotech names. Some of the larger ones have suffered as well, and when you look at the biotech indices…
Continue reading this interview: Let Volatility Power Your Micro-Cap Biotechs
About Streetwise Reports - The Life Sciences Report
Investors rely on The Life Sciences Report to share investment ideas for the biotech, pharmaceutical, medical device, and diagnostics industries. Our exclusive interviews with leading industry experts and analysts provide a clear picture of the causes of macro-economic shifts and the strategies that help you capitalize on developing trends.
DISCLOSURE:
Rexahn Pharmaceuticals Inc. is a sponsor of Streetwise Reports. Joseph Pantginis had final approval of the content and is wholly responsible for the validity of the statements. Opinions expressed are the opinions of Dr. Pantginis and not of Streetwise Reports or its officers. The interview does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of information presented here is his or her own responsibility.
Please see Streetwise Reports' terms of use and full legal disclaimer.
